Modular bioengineering of whole-cell catalysis for sialo-oligosaccharide production: coordinated co-expression of CMP-sialic acid synthetase and sialyltransferase.

3ʹ-Sialyllactose Co-expression Multienzyme cascade reaction Sialo-oligosaccharides Whole-cell bio-catalysis α2,3‐Sialyltransferase

Journal

Microbial cell factories
ISSN: 1475-2859
Titre abrégé: Microb Cell Fact
Pays: England
ID NLM: 101139812

Informations de publication

Date de publication:
27 Nov 2023
Historique:
received: 24 08 2023
accepted: 12 11 2023
medline: 29 11 2023
pubmed: 28 11 2023
entrez: 28 11 2023
Statut: epublish

Résumé

In whole-cell bio-catalysis, the biosystems engineering paradigm shifts from the global reconfiguration of cellular metabolism as in fermentation to a more focused, and more easily modularized, optimization of comparably short cascade reactions. Human milk oligosaccharides (HMO) constitute an important field for the synthetic application of cascade bio-catalysis in resting or non-living cells. Here, we analyzed the central catalytic module for synthesis of HMO-type sialo-oligosaccharides, comprised of CMP-sialic acid synthetase (CSS) and sialyltransferase (SiaT), with the specific aim of coordinated enzyme co-expression in E. coli for reaction flux optimization in whole cell conversions producing 3'-sialyllactose (3SL). Difference in enzyme specific activity (CSS from Neisseria meningitidis: 36 U/mg; α2,3-SiaT from Pasteurella dagmatis: 5.7 U/mg) was compensated by differential protein co-expression from tailored plasmid constructs, giving balance between the individual activities at a high level of both (α2,3-SiaT: 9.4 × 10 Collectively, balanced co-expression of CSS and SiaT yields an efficient (high-flux) sialylation module to support flexible development of E. coli whole-cell catalysts for sialo-oligosaccharide production.

Sections du résumé

BACKGROUND BACKGROUND
In whole-cell bio-catalysis, the biosystems engineering paradigm shifts from the global reconfiguration of cellular metabolism as in fermentation to a more focused, and more easily modularized, optimization of comparably short cascade reactions. Human milk oligosaccharides (HMO) constitute an important field for the synthetic application of cascade bio-catalysis in resting or non-living cells. Here, we analyzed the central catalytic module for synthesis of HMO-type sialo-oligosaccharides, comprised of CMP-sialic acid synthetase (CSS) and sialyltransferase (SiaT), with the specific aim of coordinated enzyme co-expression in E. coli for reaction flux optimization in whole cell conversions producing 3'-sialyllactose (3SL).
RESULTS RESULTS
Difference in enzyme specific activity (CSS from Neisseria meningitidis: 36 U/mg; α2,3-SiaT from Pasteurella dagmatis: 5.7 U/mg) was compensated by differential protein co-expression from tailored plasmid constructs, giving balance between the individual activities at a high level of both (α2,3-SiaT: 9.4 × 10
CONCLUSIONS CONCLUSIONS
Collectively, balanced co-expression of CSS and SiaT yields an efficient (high-flux) sialylation module to support flexible development of E. coli whole-cell catalysts for sialo-oligosaccharide production.

Identifiants

pubmed: 38012629
doi: 10.1186/s12934-023-02249-1
pii: 10.1186/s12934-023-02249-1
pmc: PMC10683312
doi:

Substances chimiques

N-Acylneuraminate Cytidylyltransferase EC 2.7.7.43
Oligosaccharides 0
Sialyltransferases EC 2.4.99.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

241

Subventions

Organisme : Österreichische Forschungsförderungsgesellschaft
ID : COMET K2 acib: next generation bioproduction

Informations de copyright

© 2023. The Author(s).

Références

Biotechnol J. 2020 Nov;15(11):e2000063
pubmed: 32668097
Glycobiology. 2013 Nov;23(11):1293-304
pubmed: 23969291
Metab Eng. 2002 Apr;4(2):114-23
pubmed: 12009791
Biotechnol Adv. 2023 Jan-Feb;62:108058
pubmed: 36372185
J Biotechnol. 2008 Apr 30;134(3-4):261-5
pubmed: 18378033
Biotechnol Bioeng. 2021 Nov;118(11):4290-4304
pubmed: 34289079
Chem Commun (Camb). 2021 Oct 14;57(82):10661-10674
pubmed: 34585190
Chem Rev. 2023 May 10;123(9):5521-5570
pubmed: 36584306
Curr Opin Biotechnol. 2022 Dec;78:102841
pubmed: 36371892
Biotechnol Adv. 2020 May - Jun;40:107512
pubmed: 31953205
Molecules. 2020 Aug 06;25(16):
pubmed: 32781536
Trends Biotechnol. 2023 Jun;41(6):798-816
pubmed: 36357213
Enzyme Microb Technol. 2018 Jan;108:53-58
pubmed: 29108627
Nat Commun. 2022 Jul 5;13(1):3876
pubmed: 35790733
N Biotechnol. 2015 Dec 25;32(6):658-64
pubmed: 25534674
Front Bioeng Biotechnol. 2020 Aug 06;8:854
pubmed: 32903716
Biotechnol Bioeng. 2019 Nov;116(11):2852-2863
pubmed: 31389000
Chembiochem. 2017 Aug 4;18(15):1544-1550
pubmed: 28474804
Curr Opin Biotechnol. 2022 Apr;74:55-60
pubmed: 34794111
Curr Opin Biotechnol. 2019 Apr;56:130-137
pubmed: 30502637
J Am Chem Soc. 2013 Oct 2;135(39):14831-9
pubmed: 24044869
Int J Mol Sci. 2019 Oct 23;20(21):
pubmed: 31652818
Curr Opin Biotechnol. 2019 Dec;60:221-229
pubmed: 31207555
Glycobiology. 2012 Sep;22(9):1147-62
pubmed: 22513036
Biotechnol Adv. 2021 Jan-Feb;46:107678
pubmed: 33285252
J Agric Food Chem. 2023 Feb 8;71(5):2234-2243
pubmed: 36700801
Appl Microbiol Biotechnol. 2000 Mar;53(3):257-61
pubmed: 10772462
Molecules. 2019 May 28;24(11):
pubmed: 31141914
Crit Rev Food Sci Nutr. 2022;62(1):181-214
pubmed: 32914656
Chem Rev. 2021 Sep 8;121(17):10367-10451
pubmed: 34228428
Biotechnol Adv. 2019 Sep - Oct;37(5):787-800
pubmed: 31028787
J Agric Food Chem. 2023 Apr 26;71(16):6211-6212
pubmed: 37053564
Nat Biotechnol. 2022 Mar;40(3):335-344
pubmed: 35190685
Chemistry. 2020 Sep 4;26(50):11614-11624
pubmed: 32596832
Appl Microbiol Biotechnol. 2022 Sep;106(17):5479-5493
pubmed: 35931895
Eur J Biochem. 1984 Apr 2;140(1):203-8
pubmed: 6705794
Microb Cell Fact. 2022 Apr 9;21(1):61
pubmed: 35397553
Metab Eng. 2021 Jan;63:126-140
pubmed: 32927059
ACS Synth Biol. 2022 Aug 19;11(8):2837-2845
pubmed: 35802806
Glycobiology. 2002 Apr;12(4):235-40
pubmed: 12042246
Curr Opin Biotechnol. 2023 Feb;79:102873
pubmed: 36630750
Curr Opin Biotechnol. 2023 Feb;79:102868
pubmed: 36563481
Biotechnol Adv. 2020 Nov 15;44:107613
pubmed: 32822768
Metab Eng. 2021 Jul;66:191-203
pubmed: 33895366
Org Biomol Chem. 2009 May 7;7(9):1778-80
pubmed: 19590770
Curr Opin Biotechnol. 2022 Feb;73:158-163
pubmed: 34450473
Biotechnol Adv. 2019 Nov 15;37(7):107403
pubmed: 31181317
Appl Microbiol Biotechnol. 2012 May;94(4):887-905
pubmed: 22526796
Metab Eng. 2021 Jul;66:12-20
pubmed: 33812022
Carbohydr Res. 2010 Jul 2;345(10):1394-9
pubmed: 20231015
Macromol Biosci. 2022 Dec;22(12):e2200358
pubmed: 36112275
J Agric Food Chem. 2017 Aug 30;65(34):7467-7475
pubmed: 28791861
J Biol Chem. 1991 Mar 15;266(8):4979-86
pubmed: 1900512
J Ind Microbiol Biotechnol. 2020 Aug;47(8):573-583
pubmed: 32885332
Nat Chem Biol. 2020 Aug;16(8):912-919
pubmed: 32541965
Biotechnol Bioeng. 2021 Aug;118(8):3263-3268
pubmed: 33990942

Auteurs

Sabine Schelch (S)

Austrian Centre of Industrial Biotechnology, Krenngasse 37, 8010, Graz, Austria.
Institute of Biotechnology and Biochemical Engineering, Graz University of Technology, NAWI Graz, Petersgasse 12, 8010, Graz, Austria.

Manuel Eibinger (M)

Institute of Biotechnology and Biochemical Engineering, Graz University of Technology, NAWI Graz, Petersgasse 12, 8010, Graz, Austria.

Jasmin Zuson (J)

Austrian Centre of Industrial Biotechnology, Krenngasse 37, 8010, Graz, Austria.
Institute of Biotechnology and Biochemical Engineering, Graz University of Technology, NAWI Graz, Petersgasse 12, 8010, Graz, Austria.

Jürgen Kuballa (J)

GALAB Laboratories GmbH, Am Schleusengraben 7, 21029, Hamburg, Germany.

Bernd Nidetzky (B)

Austrian Centre of Industrial Biotechnology, Krenngasse 37, 8010, Graz, Austria. bernd.nidetzky@tugraz.at.
Institute of Biotechnology and Biochemical Engineering, Graz University of Technology, NAWI Graz, Petersgasse 12, 8010, Graz, Austria. bernd.nidetzky@tugraz.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH